Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

NICE technology appraisals [TA96] Published date:

This guidance has been partially updated by CG165 Hepatitis B (chronic)

Recommendation 1.1 has been incorporated into NICE clinical guideline 165 as recommendation 1.5.8:

Peginterferon alfa-2a is recommended as an option for the initial treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative), within its licensed indications.

Recommendations 1.2, 1.3 and 1.4 have been replaced by recommendations 1.5.13, 1.5.14 and 1.5.15 in NICE clinical guideline 165.

Adefovir dipivoxil is no longer recommended for the treatment of chronic hepatitis B.

Get involved